特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
955727

COVID-19緩和製品の世界市場:将来展望 (2020~2027年)

Global COVID-19 Mitigation Products Market - 2020-2027

出版日: | 発行: DataM Intelligence | ページ情報: 英文 | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.70円
COVID-19緩和製品の世界市場:将来展望 (2020~2027年)
出版日: 2020年08月31日
発行: DataM Intelligence
ページ情報: 英文
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

新型コロナウイルス感染症 (COVID-19) の世界規模での感染拡大により、その症状緩和のための製品・サービスの需要が拡大しつつあります。FDA (米国食品医薬品局) などの行政機関が医療業界や製薬・医療機器業界、更にはその外側の組織とも協力して、必要な器材の円滑な流通に努めています。特に使い捨てマスクやPPE (個人保護具)、人工呼吸器などの調達が急がれています。

当レポートでは、世界のCOVID-19緩和製品の市場について分析し、市場の基本構造および最新情勢、全体的な市場動向の見通し (今後8年間分)、カテゴリー別 (診断用品、集中治療装置、ICT、医薬品、個人用保護具ほか) および生産設備別・エンドユーザー別・地域別の詳細動向、主な市場促進・抑制要因、市場競争構造、主要企業のプロファイル・事業戦略などについて調査しております。

目次

第1章 世界のCOVID-19緩和製品市場:分析手法・範囲

第2章 世界のCOVID-19緩和製品市場:定義と概要

第3章 世界のCOVID-19緩和製品市場:エグゼクティブサマリー

第4章 世界のCOVID-19緩和製品市場:市場力学

  • 市場への影響要因
    • 促進要因
    • 抑制要因
    • 市場機会
    • 影響力の分析

第5章 世界のCOVID-19緩和製品市場:産業分析

  • ポーターのファイブフォース分析
  • パイプライン分析
  • サプライチェーン分析
  • 価格分析
  • SWOT分析
  • 技術進歩
  • 需給分析
  • 規制分析
  • アンメットニーズ

第6章 世界のCOVID-19緩和製品市場:診断製品/サービス

  • イントロダクション
  • 市場規模の分析と対前年 (YoY) 成長率:診断製品/サービスの場合
  • 市場求心力指数:診断製品/サービスの場合
    • 血清検査キット
    • ロボット式PCR検査装置/ソフトウェア
    • PCR検査装置/ソフトウェア
    • 鼻用・口用綿棒
    • PCR検査用試薬・消耗品
    • 自己採取型PCR検査キット
    • X線処置
    • 遠隔式温度測定
    • 超音波検査
    • CT処置
    • PACS (医用画像保存システム)・テレラジオロジー (遠隔放射線診断)
    • FDG-PET/CT処置、廃水試験
    • その他

第7章 世界のCOVID-19緩和製品市場:集中治療製品/サービス

  • イントロダクション
  • 市場規模の分析と対前年 (YoY) 成長率:集中治療製品/サービスの場合
  • 市場求心力指数:集中治療製品/サービスの場合
    • 侵襲的人工呼吸器
    • 非侵襲的人工呼吸器
    • ポータブル人工呼吸器
    • 次世代型人工呼吸器
    • 腎臓透析
    • COVID-19向け在宅医療(ハードウェア、ソフトウェア、サービス)
    • 病院の緊急対応能力・ICU
    • ECMO (体外式膜型人工肺) 処置
    • その他

第8章 世界のCOVID-19緩和製品市場:医療用ICT

  • イントロダクション
  • 市場規模の分析と対前年 (YoY) 成長率:医療用ICTの場合
  • 市場求心力指数:医療用ICTの場合
    • eヘルス (電子医療)
    • 人工知能 (AI)、ビッグデータ、深層学習 (DL)
    • ブロックチェーン技術
    • 地表監視システム/サービス
    • 在宅治療用IT
    • その他

第9章 世界のCOVID-19緩和製品市場:医薬品

  • イントロダクション
  • 市場規模の分析と対前年 (YoY) 成長率:医薬品の場合
  • 市場求心力指数:医薬品の場合
    • ワクチン
    • 治療薬
    • その他

第10章 世界のCOVID-19緩和製品市場:個人用保護具

  • イントロダクション
  • 市場規模の分析と対前年 (YoY) 成長率:個人用保護具の場合
  • 市場求心力指数:個人用保護具の場合
    • 医療用手袋
    • 医療用フェイスマスク
    • 医療用ガウン
    • 手指用・顔用の消毒剤
    • 医療用フェイスシールド
    • 滅菌装置・消耗品
    • 眼球の保護
    • その他

第11章 世界のCOVID-19緩和製品市場:COVID-19関連製造プラント

  • イントロダクション
  • 市場規模の分析と対前年 (YoY) 成長率:COVID-19関連製造プラントの場合
  • 市場求心力指数:COVID-19関連製造プラントの場合
    • 人工呼吸器
    • 血清検査キット
    • 自己採取型PCR検査キット
    • PCR検査用試薬
    • PCR検査装置
    • 手袋
    • 保護具用ガウン
    • フェイスマスク
    • フェイスシールド
    • メルトブローン式PPEファブリック
    • スパンボンド式PPEファブリック
    • 鼻用・口用綿棒
    • 医療用ガラス、その他
    • 研究開発用機器・消耗品
    • その他

第12章 世界のCOVID-19緩和製品市場:エンドユーザー別

  • イントロダクション
  • 市場規模の分析と対前年 (YoY) 成長率:エンドユーザー別
  • 市場求心力指数:エンドユーザー別
    • 病院
    • 救急医療サービス(EMS)
    • 臨床検査室
    • 研究機関
    • 在宅介護施設
    • クリニック
    • その他

第13章 世界のCOVID-19緩和製品市場:地域別

  • イントロダクション
  • 市場規模の分析と対前年 (YoY) 成長率:地域別
  • 市場求心力指数:地域別
    • 北米
    • 欧州
    • 南米
    • アジア太平洋地域
    • 中東・アフリカ

第14章 世界のCOVID-19緩和製品市場:競合情勢

  • 競合シナリオ
  • 市場ポジショニング/シェア分析
  • 企業合併・買収 (M&A) の分析

第15章 世界のCOVID-19緩和製品市場:企業プロファイル

  • 3M Company
    • 企業概要
    • 製品のポートフォリオ/概略
    • 近年の動向
    • 財務分析:概要
  • Abbott
  • Agilent Technologies
  • Medtronic
  • Pfizer
  • Qualaris Healthcare Solutions
  • Allscripts Healthcare Solutions
  • Agfa Healthcare
  • AbCellera
  • 3Scan
  • Sanofi
  • Advenio Technosys
  • Siemens
  • Amara Health Analytics
  • Regeneron Pharmaceuticals
  • Avalon
  • Eli Lilly
  • Merck
  • Koninklijke Philips NV
  • その他

第16章 世界のCOVID-19緩和製品市場:重要考察

第17章 DataM Intelligenceについて

目次

Market Overview

The COVID-19 global pandemic has increased the demand for essential mitigation products and services. COVID-19 has put the pressure on medtech and pharmaceutical industry with high demand for diagnostic tests, vaccines, ventilators, personal protective equipment (PPE), and other essential medical supplies. They are taking extraordinary measures to rapidly ramp up manufacturing capacity and capabilities by adopting several strategies such as partnerships with companies outside the sector, open-source equipment layout, and deployment of medically trained employees to support public-health needs. The global COVID-19 mitigation products size was worth US$ XX billion in 2019 and is estimated to reach US$ XX trillion by 2027, growing at a CAGR of XX % during the forecast period (2020-2027).

Market Dynamics

The global COVID-19 mitigation market is growing due to several factors such as rising demand for COVID-19 vaccine, growing awareness towards protection from COVID-19 globally and rising government and non-government organizations initiatives to meet the global demand for diagnostics, protection, and other products related to COVID-19. With high COVID-19 emergencies, the FDA has taken several proactive steps to remain in contact with medical device manufacturers and others in the supply chain, including hospitals and group purchasing organizations. The FDA has reached out to over 1,000 device manufacturing sites globally, focusing on the essential devices and services. The outreach has focused on two main types of essential devices: those that are in high demand due to the COVID-19 pandemic outbreak, such as PPE and ventilators, and devices that may be prone to a potential shortage if there is a supply disruption. The FDA issued a EUA to increase the supply of filtering facepiece respirators by authorizing the use of certain imported disposable respirators that are not National Institute for Occupational Safety and Health (NIOSH)-approved for use by health care professionals. Hence, with increasing such efforts and strategies to increase the availability of devices and services, the market is expected to grow over the forecast period worldwide.

Segment Analysis

The COVID-19 pandemic is projected to show positive growth in different markets including, diagnostic products & services, pharma industry products, intensive care products & services, personal & protection gear, medical ICT, and COVID-19 related manufacturing plant.

The intensive care product & services include invasive mechanical ventilators, noninvasive ventilators, portable ventilators, next-generation ventilators, kidney dialysis, COVID-19 homecare (HW, SW, services), surge capacity hospitals & ICUs, extracorporeal membrane oxygenation procedures, and others.

Advancement in mechanical ventilators aimed to provide improved services, settling on better choices, and improving patient's comfort alongside blending of pathophysiology, medicine, and engineering to enhancing the quality of medical care in respiratory distresses. To meet rising demand worldwide, all ventilator manufacturers are ramping up their production, analyzing the criticality of the situation, even other companies such as various leading US-based car manufacturing companies are also considering manufacturing ventilators by teaming up with ventilator manufacturing companies to set up as many units as much as possible. It is estimated that in April 2020 that over 900,000 ventilators were in demand worldwide, with a shortage of 80,000 in the U.S. alone. Major companies that provide the U.S. with the devices include General Electric Co., Medtronic PLC, Hill-Rom Holdings Inc., ResMed Inc. and Sweden's Getinge AB are adopting various strategies to meet the rising demand. For instance, in the first three months of 2020, Dragerwerk AG & Co. KGaA saw a sharp rise, increasing by 116.7%. In the medical division, orders rose by 177.2%, driven primarily by demand for ventilators. On March 30th 2020, Smiths Group has made a contract with the UK Government for a significant ramp-up in the production of its life-saving Smiths Medical paraPAC plus™ ventilators. Production is expected to grow rapidly with increase from hundreds a month to thousands a month to fulfil 10,000 units in response to the UK Government's challenge to UK technology and engineering businesses to help save lives in the coronavirus pandemic.

The pharma industry is expected to grow significantly over the forecast period due to ongoing clinical trials for COVID-19 vaccine. In August 2020, about 172 economies are engaged in discussions to potentially participate in COVAX, a global initiative aimed at working with vaccine manufacturers to provide countries globally equal access to safe and effective vaccines, when they are licensed and approved. COVAX has the largest and most diverse COVID-19 vaccine portfolio globally, including nine candidate vaccines, with a further nine under evaluation and conversations underway with other major producers. COVAX, the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator, is co-led by the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, the Vaccine Alliance, and the World Health Organization (WHO), in partnership with developed and developing country vaccine manufacturers. It is the only worldwide initiative working with governments and manufacturers to ensure COVID-19 vaccines are available globally to both higher-income and lower-income countries.

Geographical Analysis

North America region is estimated to dominate the global COVID-19 mitigation products accounting for the largest market share over the forecast period. The rate of coronavirus deaths per 100,000 people in the U.S. is lower than in several European countries. By 2019, the U.S. healthcare spending stood at $3.3 trillion, more than 42% of global healthcare expenditures. By March 2020 Congress approved an unprecedented $2.2 trillion COVID-19 first relief package. It includes $161 Billion to the VA, CDC, FDA, Medicare, the Strategic National Stockpile and COVID-19 Vaccines. It does not cover the monthly deficit of $50 Billion that the Hospitals Managers Association reported. In August 2020, CDC has developed two laboratory tests that identify SARS-CoV-2, the virus that causes COVID-19. The newer of these tests are also used to test for influenza A and B viruses. Testing for all the three viruses at the same time will provide public health officials with the information they need to help reduce the spread of these viruses in the community while conserving resources that are in short supply.

Latin America has become a prime location for global COVID-19 vaccine trials, with the widespread of the virus in the community allowing developers to test the efficiency of their vaccines. Mexico is also carrying out late-stage trials for France's Sanofi, U.S. pharmaceutical giant Johnson & Johnson and two Chinese companies.

Competitive Landscape

The COVID-19 mitigation products is highly competitive and consists of several major players and emergence of new players in the market. Some of the players in the global COVID-19 mitigation products market are: 3M Company, Abbott, Sanofi, Pfizer, Eli Lilly, Merck, 3Scan, Advenio Technosys, Amara Health Analytics, Avalon, among others. The major players are adopting several growth strategies such as product launches, clinical trials, acquisitions, and collaborations, which are contributing to the growth of the COVID-19 Mitigation Products globally. For instance,

  • On November 11th 2019, Nihon Kohden has debuted its NKV-550 Series Ventilator System, which offers a full suite of applications necessary in a critical care setting for neonates through adults. The ventilator features an integrated touchscreen, intuitive user interface, and onscreen help functions.
  • On April 2nd 2020, Clensta International, a leading biotechnology company has launched the Clensta Instant Hand Hygiene Solution; an advance formula for hand sanitization. The novel product offers instant 99.9% germ protection with antimicrobial and antiseptic properties that will establish the new product as a quick solution for all-round protection and freshness.
  • In March 2020, Regeneron Pharmaceuticals and Sanofi launched a Phase II/III clinical program in the U.S. evaluating the marketed arthritis drug Kevzara (sarilumab) as a treatment for severe COVID-19 coronavirus infection in up to 400 patients.

Why Purchase the Report?

  • Visualize the composition of the COVID-19 mitigation products market by diagnostic products and services, pharma industry products, intensive care products & services, personal & protection gear, medical ICT, COVID-19 related manufacturing plants, and end-user highlighting the key commercial assets and players.
  • Identify commercial opportunities in COVID-19 mitigation products by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of COVID-19 mitigation products - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global COVID-19 mitigation products report would provide an access to an approx. 58 market data table, 54 figures and 250 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Table of Contents

1. Global COVID-19 Mitigation Products Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global COVID-19 Mitigation Products - Market Definition and Overview

3. Global COVID-19 Mitigation Products - Executive Summary

  • 3.1. Market Snippet by Diagnostic Products and Services
  • 3.2. Market Snippet by Intensive Care Products & Services
  • 3.3. Market Snippet by Pharma Industry Products
  • 3.4. Market snippet by Medical ICT
  • 3.5. Market Snippet by Personal & Protection Gear
  • 3.6. Market Snippet by COVID-19 Related Manufacturing Plant
  • 3.7. Market Snippet by End-User
  • 3.8. Market Snippet by Region

4. Global COVID-19 Mitigation Products - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising demand due to COVID-19 pandemic
      • 4.1.1.2. Growing research & development
      • 4.1.1.3. XX
    • 4.1.2. Restraints:
      • 4.1.2.1. Lack of skilled professionals and capital
      • 4.1.2.2. XX
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global COVID-19 Mitigation Products - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Pipeline Analysis
  • 5.3. Supply Chain Analysis
  • 5.4. Pricing Analysis
  • 5.5. SWOT analysis
  • 5.6. Technological Advancements
  • 5.7. Supply & Demand Analysis
  • 5.8. Regulatory Analysis
  • 5.9. Unmet Needs

6. Global COVID-19 Mitigation Products - By Diagnostic Products and Services

  • 6.1. Introduction
  • 6.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostic Products and Services
  • 6.3. Market Attractiveness Index, By Diagnostic Products and Services Segment
    • 6.3.1. Serologic Test Kits*
      • 6.3.1.1. Introduction
      • 6.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 6.3.2. Robotic PCR Systems & Software
    • 6.3.3. PCR Instrumentation & Software
    • 6.3.4. Nose & Mouth Swabs
    • 6.3.5. PCR Reagents & Consumables
    • 6.3.6. Self-collection PCR Test Kits
    • 6.3.7. X-Ray Procedures
    • 6.3.8. Standoff Thermometry
    • 6.3.9. Ultrasound Procedures
    • 6.3.10. CT Procedures
    • 6.3.11. PACS & Teleradiology
    • 6.3.12. FDG-PET/CT Procedures & Wastewater Testing
    • 6.3.13. Others

7. Global COVID-19 Mitigation Products - By Intensive Care Products & Services

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Intensive Care Products & Services
  • 7.3. Market Attractiveness Index, By Intensive Care Products & Services Segment
    • 7.3.1. Invasive Mechanical Ventilators*
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 7.3.2. Noninvasive Ventilators
    • 7.3.3. Portable Ventilators
    • 7.3.4. Next Generation Ventilators
    • 7.3.5. Kidney Dialysis
    • 7.3.6. COVID-19 Homecare (HW, SW, Services)
    • 7.3.7. Surge Capacity Hospitals & ICUs
    • 7.3.8. Extracorporeal Membrane Oxygenation Procedures
    • 7.3.9. Others

8. Global COVID-19 Mitigation Products - By Medical ICT

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Medical ICT Segment
  • 8.3. Market Attractiveness Index, By Medical ICT Segment
    • 8.3.1. E-Health*
      • 8.3.1.1. Introduction
      • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 8.3.2. AI, Big Data & Deep Learning
    • 8.3.3. Blockchain Technologies
    • 8.3.4. Geo-Surveillance Systems & Services
    • 8.3.5. Homecare IT
    • 8.3.6. Others

9. Global COVID-19 Mitigation Products - By Pharma Industry Products

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pharma Industry Products Segment
  • 9.3. Market Attractiveness Index, By Pharma Industry Products Segment
    • 9.3.1. Vaccines*
      • 9.3.1.1. Introduction
      • 9.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 9.3.2. Therapeutic Drugs
    • 9.3.3. Others

10. Global COVID-19 Mitigation Products - By Personal & Protection Gear

  • 10.1. Introduction
  • 10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Personal & Protection Gear Segment
  • 10.3. Market Attractiveness Index, By Personal & Protection Gear Segment
    • 10.3.1. Medical Gloves*
      • 10.3.1.1. Introduction
      • 10.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 10.3.2. Medical Face Masks
    • 10.3.3. Medical PPE Gowns
    • 10.3.4. Hand & Surface Sanitizers
    • 10.3.5. Medical Face Shields
    • 10.3.6. PPE Sterilization: Systems & Consumables
    • 10.3.7. Medical Eye Protection
    • 10.3.8. Others

11. Global COVID-19 Mitigation Products - By COVID-19 Related Manufacturing Plant

  • 11.1. Introduction
  • 11.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By COVID-19 Related Manufacturing Plant Segment
  • 11.3. Market Attractiveness Index, By COVID-19 Related Manufacturing Plant Segment
    • 11.3.1. Ventilators*
      • 11.3.1.1. Introduction
      • 11.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 11.3.2. Sorologic Test Kits
    • 11.3.3. Self-collection PCR Test Kits
    • 11.3.4. PCR Reagents
    • 11.3.5. PCR Systems
    • 11.3.6. Gloves
    • 11.3.7. PPE Gowns
    • 11.3.8. Face Masks
    • 11.3.9. Face Shields
    • 11.3.10. Melt-Blown PPE Fabric
    • 11.3.11. Spun-Bond PPE Fabric
    • 11.3.12. Nose & Mouth Swabs
    • 11.3.13. Medical Glass & Other
    • 11.3.14. R&D Equipment & Consumables
    • 11.3.15. Others

12. Global COVID-19 Mitigation Products - By End-User

  • 12.1. Introduction
  • 12.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User Segment
  • 12.3. Market Attractiveness Index, By End-User Segment
    • 12.3.1. Hospitals*
      • 12.3.1.1. Introduction
      • 12.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 12.3.2. Emergency Medical Services (EMS)
    • 12.3.3. Clinical Labs
    • 12.3.4. Research Bodies
    • 12.3.5. Homecare & Nursing Homes
    • 12.3.6. Clinics
    • 12.3.7. Others

13. Global COVID-19 Mitigation Products - By Region

  • 13.1. Introduction
    • 13.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
    • 13.1.2. Market Attractiveness Index, By Region
  • 13.2. North America
    • 13.2.1. Introduction
    • 13.2.2. Key Region-Specific Dynamics
    • 13.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostic Products and Services
    • 13.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Intensive Care Products & Services
    • 13.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pharma Industry Products
    • 13.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Medical ICT
    • 13.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Personal & Protection Gear
    • 13.2.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By COVID-19 Related Manufacturing Plant
    • 13.2.9. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 13.2.10. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 13.2.10.1. U.S.
      • 13.2.10.2. Canada
      • 13.2.10.3. Mexico
  • 13.3. Europe
    • 13.3.1. Introduction
    • 13.3.2. Key Region-Specific Dynamics
    • 13.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostic Products and Services
    • 13.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Intensive Care Products & Services
    • 13.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pharma Industry Products
    • 13.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Medical ICT
    • 13.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Personal & Protection Gear
    • 13.3.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By COVID-19 Related Manufacturing Plant
    • 13.3.9. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 13.3.10. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 13.3.10.1. Germany
      • 13.3.10.2. U.K.
      • 13.3.10.3. France
      • 13.3.10.4. Italy
      • 13.3.10.5. Spain
      • 13.3.10.6. Rest of Europe
  • 13.4. South America
    • 13.4.1. Introduction
    • 13.4.2. Key Region-Specific Dynamics
    • 13.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostic Products and Services
    • 13.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Intensive Care Products & Services
    • 13.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pharma Industry Products
    • 13.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Medical ICT
    • 13.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Personal & Protection Gear
    • 13.4.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By COVID-19 Related Manufacturing Plant
    • 13.4.9. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 13.4.10. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 13.4.10.1. Brazil
      • 13.4.10.2. Argentina
      • 13.4.10.3. Rest of South America
  • 13.5. Asia Pacific
    • 13.5.1. Introduction
    • 13.5.2. Key Region-Specific Dynamics
    • 13.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostic Products and Services
    • 13.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Intensive Care Products & Services
    • 13.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pharma Industry Products
    • 13.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Medical ICT
    • 13.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Personal & Protection Gear
    • 13.5.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By COVID-19 Related Manufacturing Plant
    • 13.5.9. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 13.5.10. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 13.5.10.1. China
      • 13.5.10.2. India
      • 13.5.10.3. Japan
      • 13.5.10.4. Australia
      • 13.5.10.5. Rest of Asia Pacific
  • 13.6. Middle East and Africa
    • 13.6.1. Introduction
    • 13.6.2. Key Region-Specific Dynamics
    • 13.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug
    • 13.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostic Products and Services
    • 13.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Intensive Care Products & Services
    • 13.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pharma Industry Products
    • 13.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Medical ICT
    • 13.6.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Personal & Protection Gear
    • 13.6.9. Market Size Analysis, and Y-o-Y Growth Analysis (%), By COVID-19 Related Manufacturing Plant
    • 13.6.10. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User

14. Global COVID-19 Mitigation Products - Competitive Landscape

  • 14.1. Competitive Scenario
  • 14.2. Market Positioning/Share Analysis
  • 14.3. Mergers and Acquisitions Analysis

15. Global COVID-19 Mitigation Products- Company Profiles

  • 15.1. 3M Company*
    • 15.1.1. Company Overview
    • 15.1.2. Product Portfolio and Description
    • 15.1.3. Key Highlights
    • 15.1.4. Financial Overview
  • 15.2. Abbott
  • 15.3. Agilent Technologies
  • 15.4. Medtronic
  • 15.5. Pfizer
  • 15.6. Qualaris Healthcare Solutions
  • 15.7. Allscripts Healthcare Solutions
  • 15.8. Agfa Healthcare
  • 15.9. AbCellera
  • 15.10. 3Scan
  • 15.11. Sanofi
  • 15.12. Advenio Technosys
  • 15.13. Siemens
  • 15.14. Amara Health Analytics
  • 15.15. Regeneron Pharmaceuticals
  • 15.16. Avalon
  • 15.17. Eli Lilly
  • 15.18. Merck
  • 15.19. Koninklijke Philips NV
  • 15.20. Others

LIST NOT EXHAUSTIVE

16. Global COVID-19 Mitigation Products - Premium Insights

17. Global COVID-19 Mitigation Products - DataM

  • 17.1. Appendix
  • 17.2. About Us and Services
  • 17.3. Contact Us
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.